Pages 24-32

Öz

-

Anahtar Kelimeler

• -

Periodontal Hastalık ve Lipoksinler

Öz

Enflamatuvar cevap başladığında, kademeli devam eden bir dizi olay meydana gelir. Bu dizi olaylar sırasında, vücut, hücrelerin pro-enflamatuvar etkileri ve ürünleriyle istilacıları elimine etmeye çalışır. Enflamasyonun rezolüsyonu son derece koordineli ve aktif bir süreçtir. Enflamasyonun rezolüsyon süreci, pro-enflamatuvar mekanizmalara benzer olarak, enflamatuvar hücrelerinin temizlenmesine ve kapatılmasına neden olan dur sinyalleri üretmek için hücreleri ve hücreler tarafından oluşturulmuş haberci molekülleri kullanır. Endojen lipit-kökenli mediyatörler konak cevabını düzenlerler ve enflamasyonun rezolüsyonunu koordine ederler. Lipoksinler (LX) ve 15 epimerleri, aspirin-indüklü lipoksinler (ATL), araşidonik asitlerin ardışık lipoksijenaz (LO) metabolizmalarından köken alan eikosanoidlerdir. Lipoksin biyosentezinin ana rotası, 15- ve 5-LO ile 12- ve 5-LO arasındaki kooperasyonu içerir. Lipoksin ve ATL’nin anti-enflamatuvar, prorezolüsyon biyoetkilerini gösteren kanıtlar yıllardır pekiştirilmektedir. Lipoksin A4, ATL ve analoglarının, artrit, gastrointestinal, böbrek, respiratuar, vasküler enflammatuvar hastalıklar, göz hasarları, periodontitis, seçici enfeksiyöz hastalıkları içeren hastalıkların hayvan modellerinde ve hastalıkların in vitro modellerindeki anlamlı etkileri, insan hastalıklarının tedavisinde olası kullanımlarını desteklemektedir

Anahtar Kelimeler

• Periodontal hastalık, lipoksin, aspirin-indüklü lipoksin, araşidonik asit, rezolüsyon

Kaynakça

1. Serhan CN, Jain A, Marleau S et al. Reduced inflammation an tissue damage in transgenic rabbits overexpressing 15-lipoxyge-nase and endogenous anti- inflammatory lipid mediators. J Immunol 2003; 171: 6856-6865.
2. Van Dyke TE, Serhan CN. Resolution of inflammation: a new paradigm for the pathogenesis of periodontal diseases. J Dent Res 2003; 82: 82- 90.
3. Perretti M, Chiang N, La M et al. Endegenous lipid- pathways generated with glucocorticoid and aspirin treatment activate the lipoxin A4 receptor. Nat Med 2002; 8: 1296-1302. anti-inflammatory
4. Gilroy DW, Lawrence T, Perretti M et al. Inflammatory resolution: new opportunities for drug discovery. Nat Rev Drug Discov 2004; 3: 401- 416.
5. Kumar V, Abbas AK, Fausto N. Robbins and Cotran Pathologic Basis of Disease. Elsevier Saunders, Philadelphia, 2005.
6. Serhan CN. Resolution phase of inflammation: novel proresolving lipid mediators and pathways. Annu Rev Immunol 2007; 25: 101-137. and
7. Preshaw PM, Taylor JJ. Periodontal Pathogenesis. In: Carranza’s Clinical Periodontology. Newman MG, Takei HH, Klokkevold PR, Carranza FA. Elsevier Saunders, 11th ed., 205.
8. Cotran RS, Kumar V, Collins T. Cellulapathology I. Cell injury and cell death. Saunders, Philadelphia, 1999, 1-29.

9. Van Dyke TE. Control of inflammation and periodontitis. Periodontol 2000 2007; 45: 158-166.
10. Kumar V, Abbas AK, Fausto N et al. Robbins Basic Pathology. 8th ed, Philadelphia, Saunders, 2007.
11. Simopoulos AP, Leaf A, Salem N Jr. Workshop on the essentiality of and recommended dietary intakes for omega-6 and omega-3 fatty acids. J Am Coll Nur 1999; 18: 487-489.
12. Burr GO, Burr MM. A new deficiency disease produced by the rigid exclusion of fat from the diet. J Biol Chem 1929; 82: 345.
13. Lands WEM. Diets could prevent many diseases. Lipids 2003; 38: 317-321.
14. Bazan NG. Supply of n-3 polyunsaturated fatty acids and their significance in the central nervous system. In: Wurtman RJ, Wurtman JJ, editors. Nutrition and The Brain. New York, Raven Press, 199, 1-22.
15. Salem N Jr, Litman B, Kim HY et al. Mechanism of action of docosahexaenoic acid in the nervous system. Lipids 2001; 36: 945-959.
16. Kelley DS. Modulation of human immune and inflammatory responses by dietary fatty acids. Nutrition 2001; 17 (7-8): 669-673.
17. Benito P. The effect of conjugated linoleic acid on platelet function, platelet fatty acid composition, and blood coagulation in humans. Lipids 2001; 36 (3): 221-227. 18. Murakami M. Regulatory phospholipase A2. Crit. Rev Immunol 1997; 17 (3- 4): 225-283. functions of
18. Hamberg M., Samuelsson B. Prostaglandins in human seminal plasma. Prostaglandins and related factors 46. J Biol Chem 1966; 241 (2): 257-263. 20. Hamberg M, Svensson J, Samuelsson B. Thromboxanes: A new group of biologically active compounds endoperoxides. Proc Natl Acad Sci 1975; 72 (8): 2994-2998. from prostaglandin 21. Yoshikai Y. Roles of leukotrienes in acute inflammation caused by bacterial infection. Curr Opin Infect Dis 2001; 14 (3): 257-263. prostaglandins and
19. Samuelsson B. An elucidation of the arachidonic acid thromboxane and leukotrienes. Drugs 33 1987; (Suppl. 1): 2-9. of progtaglandins,
20. Higgs GA. Polymorphonuclear leukocytes produce thromboxane A2-like activity during phagocytosis. Prostaglandins 1976; 12 (5):749-757.
21. Vane JR. The mode of action of aspirin and similar compounds, J Allergy Clin Immunol 1976; 58 (6): 691-712. 25. Vane JR.
22. Prostaglandins as mediators of
23. inflammation. Adv Prostaglandin Thromboxane
24. Res 1976; 2: 791-801.
25. Banion MKO’, Winn VD, Young DA. cDNA cloning and functional activity of a glucocorticoid- regulated inflammatory cyclooxgenase. Proc Natl Acad Sci 1992; 89 (11): 4888-4892. 27. Banion M.K.O’.
26. Cyclooxgenase-2:molecular
27. biology, pharmacology, and neurobiology, Crit Rev
28. Neurobiol 1999; 13 (1): 45-82.
29. Banion MKO’, Olschowka JA. Localization and distribution of cyclooxgenase-2 inbrain tissue by immunohistochemistry. Methods Mol Biol 1999; 120: 55-66.
30. Samuelsson B, The leukotrienes: an introduction. Adv Prostaglandin Thromboxane Leukot Res 1982; 9: 1-17.
31. Serhan CN, Drazen JM. Antiinflammatory potential of lipoxygenase-derived eicosanoids: a molecular switch at 5 and 15 positions?. J Clin Invest 1997; 99 (6): 1147-1148. CD. 31. Funk
32. Prostaglandins and leukotrienes:
33. advances in eicosanid biology. Science 2001; 294 (5548): 1871-1875.
34. Bandeira-Melo-C, Bozza PT, Weller PF. The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 2002; 109 (3): 393-400.
35. Diamond P, McGinty A, Sugrue D et al. Regulation of leukocyte trafficking by lipoxins. Clin Chem Lab Med 1999; 37: 293-297.
36. Samuelsson B. Leukotrienes structures, biosynthesis, and biological effects. Science 1987; 237 (4819): 1171-1176. lipoxins:
37. Serhan CN, Sheppard KA. Lipoxin formation during human neutrophil-platelet interactions. Evidence for the transformation of leukotriene A4 by platelet 12-lipoxygenase in vitro. J Clin Invest 1990; 85 (3): 772-780.
38. Serhan CN, Fiore S, Levy BD. Cell-cell interactions characterization of lipoxin A4 receptors. Ann NY Acad Sci 1994; 744: 166-180. generation and
39. Levy BD. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol 2001; 2 (7): 612-619.
40. Brady HR, Serhan CN. Lipoxins: putative braking signals in host defense, inflammation and hypersensivity. Curr Opin Nephrol Hypertens 1996; 5 (1): 20-27.
41. Serhan CN, Hamberg M, Samuelsson B. Lipoxins: novel series of biologically active compounds formed from arachidonic acid in human leukocytes. Proc Natl Acad Sci 1984; 81 (17): 5335-5339.
42. Badr KF. Lipoxin A4 antagonizes cellular and in vivo actions of leukotriene D4 in rat glomerular mesangial cells:evidence of competition ata common receptor. Proc Natl Acad Sci 1989; 86 (9): 3438-3442.
43. Lee TH. Inhibition of leukotriene B4-induced neutrophil migration by lipoxin A4: structure- function relationships. Biochem Biophys Res Commun 1991; 180 (3): 1416-1421.
44. Serhan CN, Romano M. Lipoxin biosynthesis and actions: role of the human platelet LX-synthase. J Lipid Mediat Cell Signal 1995; 12 (2-3): 293-306.
45. Brezinski ME, Serhan CN. Selective incorporation of phosphatidylinositol of human neutrophils: agonist- induced deacylation and transformation of stored hydroxyeicosanoids. Proc Natl Acad Sci 1990; 87 (16) : 6248-6252. acid in
46. Claria J, Serhan CN. Aspirin triggers previously undescribed bioactive eicosanoids by human endothelial cell-leukocyte interactions. Proc Natl Acad Sci 1995; 92 (21): 9475-9479. 45. Edenius C, Haeggstrom conversion JA. Transcellular arachidonic acid to lipoxins in mixed human platelet-granulocye suspensions. Biochem Biophys Res Commun 1988; 157: 801-807. endogenous
47. Fiore S, Serhan CN. Formation of lipoxins and leukotrienes during receptor mediated interactions of human platelets and recombinant human granulocyte/macrophage colony-stimulatig actor- primed neutrophils. J Exp Med 1990; 72: 1451- 1457.
48. Romano M, Serhan CN. Lipoxin generation by permeabilized human platelets Biochemistry 1992; 31: 8269-8277.
49. Sheppard KA, Greenberg SM, Funk CD et al. Lipoxin generation by human megakaryocyte- induced 12-lipoxygenase. Biochim Biophys Acta 1992; 1133: 223-234.
50. Romano M, Chen XS, Takahashi Y et al. Lipoxin synthase lipoxygenase. Biochem J 1993; 296(Pt 1): 127-133. human platelet 12
51. Lehr HA, Olofsson AM, Carew TE et al. P-selectin mediates the interaction of circulating leukocytes with platelets and microvascular endothelium in response to oxidized lipoprotein in vivo. Lab Invest 1994; 71: 380-386.
52. Mayadas TN, Mendrick DL, Brady HR et al. Acute passive nephritis in P-selectin-deficient mice. Kidney Int 1996; 49: 1342-1349. basement membrane
53. Fiore S, Serhan CN. Phospholipid bilayers enhance the stability of leukotriene A4 and epoxytetraenes: stabilization of eicosanoids by liposomes. Biochem Biophys Res Commun 1989; 159:477-481.
54. Krump E, Picard S, Mancini I et al. Suppression of leukotriene B4 biosynthesis by endogenous adenosine in liga-and-activated human neutrophils. J Exp Med 1997; 186: 1401-1406.
55. Edenius C, Kumlin M, Bjork et al. Lipoxin formation in human nasal polyps and bronchial tissue. FEBS Lett 1990; 272: 25-28.
56. Garrick R, Wong PY. Enzymatic formation and regulatory function of lipoxins and leukotriene B4 in rat kidney mesangial cells. Adv Exp Med Biol 1991; 314: 361-369.
57. Edenius C, Stenke L, Lindgren A. On the mechanism of transcellular lipoxin formation in human platelets and granulocytes. Eur J Biochem 1991; 199: 401-409.
58. Tornhamre S, Gigou A, Edenius C et al. Conversion of 5,6-dihydroxyeicosatetraenoic acids. A novel pathway for lipoxin formation by human platelets. FEBS Lett 1992; 304: 78-82.
59. Chavis C, Vachier I, Chanez P et al. 5(S), 15(S)- Dihyddroxyeicosatetraenoic generation in human polymorphonuclear cells dual specificity of lipoxygenase towards endogenous and exogenous precursors. J Exp Med 1996; 183: 1633-1643. acid and lipoxin
60. Thomas E, Leroux JL, Blotman F. Conversion of endogenous arachidonic acid to 5,15-diHETE and lipoxins by polymorphonuclear cells from patients with rheumatoid arthritis. Inflamm Res 1995; 44: 121-124.
61. Herschman HR. Prostaglandin synthase 2. Biochim Biophys Acta 1996; 1299: 125-140.
62. Serhan CN, Maddox J, Petasis NA et al. Design of lipoxin A4 stable analogs that block transmigration and adhesion of human neutrophils. Biochemistry 1995; 34: 14609-14615.
63. Levy GN. Prostaglandin H synthases, nonsteroidal antiinflammatory drugs and colon cancer. FASEB J 1997; 11: 234-247.
64. Fierro IM, Kutok JL, Serhan CN. Novel lipd mediator regulators of endothelial cell proliferation and migration: aspirin-triggered -15R-lipoxin A(4) and lipoxin A(4). J Pharmacol Exp Ther 2002; 300: 385-392.
65. Kantarcı A and Van Dyke TE. Lipoxins in chronic ınflammation. Crit Rev Oral Biol Med 2003; 14: 4.
66. Lee TH, Crea AE, Gant V et al. Identification of lipoxin A4 and its relationship to the sulfidopeptide leukotrienes C4 , D4 and E4 in the bronchoalveolar lavage fluids obtaine from patients with selected pulmonary diseases. Am Rev Respir Dis 1990; 141: 1453-1458.
67. Papayianni A, Serhan CN, Phillips M et al. Transcellular biosynthesis of lipoxin a4 during adhesion experimental immune complex glomerulonephritis. Kidney Int 1995; 47: 1295-1302. neutrophils in
68. Chavis C, Vachier I, Godard P et al. Lipoxins and other arachidonate derived mediators in bronchial asthma. Thorax 2000; 55(Supple)2: 38-41.
69. Brezinski DA, Nesto RW, Serhan CN. Angioplasty triggersintracoronary leukotrienes and lipoxin A4. Impact of aspirin therapy. Circulation 1992; 86: 56- 63.
70. Stenke L, Reizenstein P, Lindgren JA. Leukotrienes and lipoxins-new potential performers in the regulation of human myelopoiesis. Leukemia Res 1994; 18: 727-732.
71. Chiang N, Takano T, Clish CB et al. Aspirin triggered 15-epi-lipoxin A4 (ATL) generation by human leukocytes and murine peritonitis exudates: development of a specific 15-epi-LXA4 ELISA. J Pharmacol Exp Ther 1998; 287: 779-790.
72. Sanak M, Levy BD, Clish CB et al. Aspirin-tolerant asthmatics generate more lipoxins than aspirin- intolerant asthmatics. Eur Respir J 2000; 16: 44-49.
73. Stenke L, Edenius C, Samuelsson B et al. Deficient lipoxin synthesis: a novel platelet dysfunction in myeloproliferative disorders with special reference to blastic crisis of chronic myelogenous leukemia. Blood 1991; 78: 2989-2995.
74. Claria J, Titos E, Jimenez W et al. Altered biosynthesis of leukotrienes and lipoxins and host defense disorders in patients with cirrhosis and ascites. Gastroenterology 1998; 115: 147-156.
75. Pouliot M, Clish CB, Petasis NA et al. Lipoxin A4 analogues Porphyromonas cyclooxygenase-2 and lipoxins in periodontal disease. Biochemistry 2000; 39: 4761-4768. to for gingivalis:
76. Dewhirst FE, Moss DE, Offenbacher S et al. Levels of prostaglandin E2, thromboxane, and prostacyclin in periodontal tissue. J Periodonal Res 1983; 18: 156-163.
77. Romano M. Lipoxin and Aspirin-Triggered Lipoxins. The Sci World J 2010; 10: 1048-1064.
78. Fierro IM, Colgan SP, Bernasconi G et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit human neutrophil migration: comparisons between synthetic transmigration with microvessel endothelial cells and epithelial cells. J. Immunol. 2003; 170: 2688– 2694. in chemotaxis and
79. Scalia R, Gefen J, Petasis NA et al. Lipoxin A4 stable analogs inhibit leukocyte rolling and adherence in the rat mesenteric microvasculature: role of P-selectin. Proc Natl Acad Sci 1997; 94: 9967–9972.
80. Bandeira-Melo C, Bozza PT, Diaz BL et al. Cutting edge: lipoxin (LX) A4 and aspirin-triggered 15-epi- LXA4 trafficking. J Immunol 2000; 164: 2267–2271.
81. Jozsef L, Zouki C, Petasis NA et al. Lipoxin A4 and aspirin-triggered 15-epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene expression in human leukocytes. Proc Natl Acad Sci 2002; 99: 13266– 13271.
82. Gewirtz AT, Fokin VV, Petasis NA et al. LXA4, aspirin-triggered 15-epi-LXA4, and their analogs selectively degranulation. Am J Physiol 1999; 276: 988–994.
83. Sodin-Semrl S, Taddeo B, Tseng D et al. Lipoxin A4 inhibits IL-1 beta-induced IL-6, IL-8, and matrix metalloproteinase-3 production in human synovial fibroblasts and enhances synthesis of tissue inhibitors of metalloproteinases. J Immunol 2000; 164: 2660–2666.
84. Hachicha M, Pouliot M, Petasis NA et al. Lipoxin (LX)A4 and aspirin-triggered 15-epi-LXA4 inhibit tumor necrosis factor 1alpha-initiated neutrophil responses and trafficking: regulators of a cytokine- chemokine axis. J Exp Med 1999; 189: 1923–1930.
85. Bannenberg GL, Chiang N, Ariel A et al. Molecular circuits of resolution: formation and actions of resolvins and protectins. J Immunol 2005; 174: 4345–4355.
86. Cezar-de-Mello PF, Vieira AM, Nascimento-Silva V et al. ATL-1, an analogue of aspirin-triggered lipoxin A4, is a potent inhibitor of several steps in angiogenesis induced by vascular endothelial growth factor. Br J Pharmacol 2008; 153: 956–965.
87. Baker N, O'Meara SJ, Scannell M et al. Lipoxin A4: anti-inflammatory and anti-angiogenic impact on endothelial cells. J Immunol 2009; 182: 3819– 3826.
88. Leedom AJ, Sullivan AB, Dong B et al. Endogenous LXA4 circuits are determinants of pathological angiogenesis in response to chronic injury. Am J Pathol 2010; 176: 74–84.
89. Takano T, Clish CB, Gronert K et al. Neutrophil- mediated changes in vascular permeability are inhibited by topical application of aspirin-triggered 15-epi-lipoxin A4 and novel lipoxin B4 stable analogues. J Clin İnvest 1998; 101: 819-826.
90. Maddox JF, Colgan SP, Clish CB et al. Lipoxin B4 regulates human monocyte/neutrophil adherence and motility: design of stable lipoxin-analogs with increased biologic activity. FASEB J 1998; 12: 487-494. Sorumlu Yazar:
91. Meltem Karşıyaka Hendek
92. Kırıkkale Üniversitesi, Dişhekimliği Fakültesi
93. Periodontoloji Anabilim Dalı Kırıkkale/TÜRKİYE
94. Tel: [phone]/ 3535
95. Fax: [phone]
96. e-mail: [e-mail]